Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs) Violetta Dymicka-PiekarskaOlga M. Koper-LenkiewiczJoanna Kamińska Review Open access 03 November 2020 Pages: 1497 - 1510
Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature Fausto MeriggiAlberto Zaniboni Review 09 November 2020 Pages: 1511 - 1517
Epstein–Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma O. JimenezS. ColliP. Chabay Original Article 12 November 2020 Pages: 1519 - 1526
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review Zhe ZhaoXinfeng WangDan Zhang Original Article 16 November 2020 Pages: 1527 - 1540
microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy Gilli Galore-HaskelEyal GreenbergGal Markel Original Article 17 November 2020 Pages: 1541 - 1555
Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma Nuchjira TakheawGunya SittithumchareeSeiji Okada Original Article 19 November 2020 Pages: 1557 - 1567
Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo G. de JongL. BartelsK. Wagner Original Article 23 November 2020 Pages: 1569 - 1581
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study Vincenzo Di NoiaEttore D’ArgentoEmilio Bria Original Article Open access 24 November 2020 Pages: 1583 - 1592
Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab Nalee KimJeong Il YuKyunga Kim Original Article 24 November 2020 Pages: 1593 - 1603
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy Changhee ParkKyeonghun JeongDae Seog Heo Original Article 24 November 2020 Pages: 1605 - 1617
Let-7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-13 and IL-10 Boxing SuHaibo HanLiqun Zhou Original Article 25 November 2020 Pages: 1619 - 1634
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes Lukas PeifferFarnoush FarahpourJürgen C. Becker Original Article Open access 04 December 2020 Pages: 1635 - 1647
Comprehensive genomic and immunophenotypic analysis of CD4 T cell infiltrating human triple-negative breast cancer He ZhangGuohui QinSha Zhu Original Article Open access 10 December 2020 Pages: 1649 - 1665
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC Marzia Del ReFederico CucchiaraRomano Danesi Original Article Open access 14 December 2020 Pages: 1667 - 1678
The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations Barbara WillvonsederFabian StögbauerMelanie Boxberg Original Article Open access 19 December 2020 Pages: 1679 - 1689
Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents Carlos ZamoraMariona RiudavetsSilvia Vidal Original Article 02 January 2021 Pages: 1691 - 1704
Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma Ming YiAnping LiKongming Wu Original Article Open access 02 January 2021 Pages: 1705 - 1719
Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers Qingzhu LiuLei JiangLing Qiu Original Article 02 January 2021 Pages: 1721 - 1733
Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer Gisela María SuárezAna Laura Añé-KouríAgustin Lage Original Article 02 January 2021 Pages: 1735 - 1743
Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors Shinkichi TakamoriKazuki TakadaMasaki Mori Original Article 03 January 2021 Pages: 1745 - 1753
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues Shin Hye YooJihui YunDae Seog Heo Original Article 03 January 2021 Pages: 1755 - 1769
The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro Mario PrestiMarie Christine Wulff WestergaardMarco Donia Research Report 09 November 2020 Pages: 1771 - 1776
Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years Fausto PetrelliAlessandro InnoMelissa Bersanelli Research Report 10 November 2020 Pages: 1777 - 1780
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab) Simon FietzRomina ZarblDimo Dietrich Research Report Open access 16 November 2020 Pages: 1781 - 1788
Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy Qingsheng LiPhuong T. NgoNejat K. Egilmez Research Report 27 November 2020 Pages: 1789 - 1796